К основному контенту

Eating out could put you and your kids at risk

 You know that too much salt contributes to high blood pressure, but you might not realize how easily eating out could put you and your kids at risk.


Many entrees at leading restaurants and fast food places contain almost a full day's allotment of salt, according to the U.S. Centers for Disease Control and Prevention. Remember, that's 2,300 milligrams, or about one teaspoon.

With many Americans eating out an average of five times a week, all that salt adds up. And the more salt you eat, the greater the odds for high blood pressure (hypertension), a major contributor to heart disease and stroke.

By some estimates, the average American takes in 50 percent more salt than the daily limit, and this excess starts in childhood. Kids between 6 and 10 years of age take in 2,900 mg a day, while teens top out at about 3,700 mg.

Studies done around the world have looked at salt consumption and high blood pressure. A study of 500 people, aged 18 to 40, found that the more restaurant meals people ate every week, the higher their odds of pre-hypertension. Young people with even a slightly elevated blood pressure level are at very high risk of full-blown hypertension.

About 80 percent of the salt consumed has been added by manufacturers of processed foods or at restaurants. While the salt in hundreds of processed foods has gone down slightly in recent years, a Harvard study reported that it has gone up in many fast food items.

To protect yourself and your family when dining out, ask about the salt content of meals you're thinking of ordering. Restaurants with 20 or more locations must provide this on request, and many chains post the numbers online. Finally, resist reaching for the salt shaker.


© 2019 HealthDay. All rights reserved.

Комментарии

  1. A vape pen exploded in the face of 17-year-old Nevada boy, breaking his jaw and requiring multiple surgeries to repair the damage, according to a case report in the latest New England Journal of Medicine.
    The 2018 incident highlights a little-known danger of e-cigarettes -- the devices can unexpectedly blow up, causing burns and severe facial damage.
    "He was [using] this vape pen, and it blew up in his face while he was [using] it," said one of the doctors who treated him, Dr. Katie Russell, a pediatric surgeon at the University of Utah in Salt Lake City.
    The e-cigarette blast was strong enough to break bones and blow out teeth.
    "He broke his lower jaw, which takes a large amount of force," Russell said. Doctors had to insert a two-inch plate on his lower jaw to stabilize the fracture.
    "His jaw was wired shut for about six weeks," she said. "He could only eat soft food for six weeks, until it healed, and then he had to come back and have another operation to get those wires removed."
    Although the boy has fully recovered from his injuries, he still has three or four teeth missing, because he's lacked the insurance coverage to afford to have them replaced, Russell said.
    "He's still missing all those teeth, but he's hoping to get them fixed this summer," she added.

    ОтветитьУдалить

Отправить комментарий

Популярные сообщения из этого блога

A healthy diet may trigger a better response to a certain kind of melanoma treatment. How?

New research suggests that a diet that's full of fiber appears to lead to more diverse intestinal bacteria (microbiome). In turn, a thriving gut microbiome is linked to a stronger response to an immune therapy for the aggressive skin cancer. "We found that patients eating a high-fiber diet at the start of therapy were about five times more likely to respond to the anti-PD-1 immunotherapy," said study author Christine Spencer. She's a research scientist with the Parker Institute for Cancer Immunotherapy in San Francisco. Anti-PD-1 immunotherapy helps the immune system recognize cancer cells as dangerous cells that need to be destroyed, according to the American Cancer Society (ACS). The cancer drugs Keytruda and Opdivo are examples of this type of immunotherapy. Melanoma is a type of skin cancer. It only accounts for about 1 percent of all skin cancers, but is responsible for most skin cancer deaths, the ACS says. Several recent studies have suggested that a ...

American Heart Association News

On Feb. 1, 1961, twins Debbie and Donna Horst arrived at the White House to fanfare. The 6-year-olds, decked out in fancy dresses and satin sashes, found themselves surrounded by a pressing crowd and a sea of blinding flashbulbs as they made their way to see Jacqueline Kennedy. The girls -- both born with holes in their aortas -- were meeting with the first lady to kick off a national campaign to raise awareness about congenital heart defects. "There were hundreds of reporters because this was Jacqueline Kennedy' first public act as first lady," Debbie said. She recalls being startled when the reporters asked Mrs. Kennedy if they could move in closer. "It was frightening because they all jumped at us at once." The Pennsylvania twins, just a few weeks from turning 7, were among the first "Heart Fund Sweethearts" in the campaign to raise money as well as awareness. The month before, they'd met up with Micki and Patricia Gane, also of Pennsylvania...

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla®, an investigational low-dose combined hormonal contraceptive patch (AG200-15).  Agile resubmitted the NDA in response to a December 2017 Complete Response Letter (CRL) from the FDA, which identified deficiencies relating to (i) quality control adhesion test methods for the Twirla manufacturing process, (ii) observations identified during an inspection of a facility of our third-party manufacturer for the Twirla NDA that must be resolved, and (iii) questions on the in vivo adhesion properties of Twirla and their potential relationship to the SECURE clinical trial results. The resubmitted NDA includes the results from a...